Activated Partial Thromboplastin Time

The activated partial thromboplastin time (aPTT) is a critical blood test used to evaluate the speed of blood clot formation through the intrinsic and common coagulation pathways, assessing factors such as I, II, V, VIII, IX, X, XI, and XII. 

Unlike the partial thromboplastin time (PTT), the aPTT includes an activator that speeds up clotting, offering a narrower reference range and enhanced sensitivity.  

This test is pivotal in monitoring heparin therapy, ensuring that dosages are precisely adjusted to achieve optimal anticoagulation and reduce the risks of bleeding or thrombosis.  

Elevated aPTT readings can indicate clotting factor deficiencies or the presence of inhibitors, while shortened aPTT may suggest conditions like disseminated intravascular coagulation or the immediate aftermath of severe blood loss. 

Additionally, the aPTT is employed extensively to screen for various coagulation disorders, making it an essential tool in both diagnostic and therapeutic contexts.

Understanding aPTT  [1., 6.]

The activated partial thromboplastin time (aPTT) is a blood test that measures the overall speed of blood clot formation by assessing the intrinsic and common coagulation pathways.  It indirectly measures the function of coagulation factors I, II, V, VIII, IX, X, XI, and XII.  [6.] 

The activated partial thromboplastin time (aPTT) is a more sensitive version of the partial thromboplastin time (PTT), which is used to assess the intrinsic and common coagulation pathways. 

Both tests measure the overall speed of blood clot formation, but in the aPTT, an activator is added that speeds up the clotting time, resulting in a narrower reference range compared to the PTT.

The aPTT is commonly used to monitor a patient's response to heparin therapy, as it provides a more accurate assessment of the anticoagulant effect.  Heparin acts by enhancing the activity of antithrombin, which inhibits thrombin and other activated clotting factors, leading to prolonged aPTT values. 

By closely monitoring the aPTT, healthcare providers can adjust heparin dosages to maintain the desired level of anticoagulation and minimize the risk of bleeding or thrombosis.

Prolonged aPTT values may indicate deficiencies in clotting factors or the presence of inhibitors, while shortened aPTT can be seen in conditions like disseminated intravascular coagulation.  The aPTT is also commonly used to screen for coagulation disorders. 

Laboratory Testing for aPTT

Laboratory testing for activated partial thromboplastin time (aPTT) is essential for diagnosing and monitoring coagulation disorders. 

Overview of aPTT Testing Procedure, Sample Requirements and Preparation

To perform the test, a blood sample is collected from a vein in the arm.  The plasma is mixed with an activator (such as silica, celite, kaolin, or ellagic acid) and phospholipids, and calcium is added to initiate clotting.

Special preparation is typically not required, although healthcare providers may have specific instructions regarding medication or anticoagulant use.  

Interpretation of aPTT Results

Optimal Levels of aPTT

Optimal levels of aPTT are considered 30-40 seconds.  [4.]

Prolonged aPTT Levels  [2., 5.]

A prolonged activated partial thromboplastin time (aPTT) may indicate several conditions, including congenital deficiencies of intrinsic system clotting factors (such as Factors VIII, IX, XI, and XII), which encompass disorders like hemophilia A and B. 

Other potential causes are von Willebrand disease, the most common inherited bleeding disorder that affects platelet function due to reduced von Willebrand factor activity, and hypofibrinogenemia.  

Liver diseases like cirrhosis can prolong aPTT due to decreased production of clotting factors, a function normally facilitated by the liver.  Similarly, vitamin K deficiency can lead to insufficient clotting factors, since vitamin K is essential for their synthesis. 

Conditions such as disseminated intravascular coagulation (DIC), where clotting factors are consumed, also prolong aPTT. 

Pharmaceutical agents like heparin and coumarin, which inhibit the intrinsic pathway and the function of specific clotting factors respectively, can also extend aPTT. 

Additionally, nonspecific inhibitors such as lupus anticoagulant and anticardiolipin antibodies, and specific circulating anticoagulants from inhibitor antibodies targeting coagulation factors, often seen in systemic autoimmune or infectious diseases, may cause prolonged aPTT.

Shortened aPTT Levels  [2., 5.]

A shortened activated partial thromboplastin time (aPTT) can signal several clinical scenarios of concern.  In the early stages of disseminated intravascular coagulation (DIC), circulating procoagulants can shorten the aPTT, indicating an increased clotting tendency.

 This condition is also common in extensive cancers, such as ovarian, pancreatic, and colon cancer, where abnormal clotting behavior is frequently observed.  

A shortened aPTT may also occur immediately following an acute hemorrhage, as the body rapidly responds to blood loss.  Additionally, an acute-phase response, which often elevates factor VIII levels, can similarly reduce aPTT, reflecting heightened clotting activity. 

Each of these situations suggests an increased risk of thrombosis and warrants careful clinical assessment and management.

Related Biomarkers in Coagulation Assessment

In addition to activated partial thromboplastin time (aPTT), various other biomarkers play pivotal roles in assessing coagulation function and identifying underlying disorders. 

Prothrombin Time (PT)  [8.]

Prothrombin time measures the time it takes for blood to clot after the addition of tissue factor, which activates the extrinsic pathway of coagulation.  

PT primarily assesses the integrity of the extrinsic and common pathways, providing information on factors such as prothrombin, factors V, VII, and X. 

Abnormalities in PT may indicate deficiencies or dysfunction in these factors and are commonly seen in conditions such as vitamin K deficiency, liver disease, and the presence of anticoagulant medications.

Thrombin Time (TT)  [7.] 

Thrombin time evaluates the time it takes for fibrinogen to convert to fibrin in the presence of thrombin. TT primarily assesses the functionality of fibrinogen and its conversion to fibrin, providing insights into the final step of the coagulation cascade. 

Prolonged TT values may indicate deficiencies in fibrinogen levels or dysfunction in fibrinogen function, as seen in conditions such as afibrinogenemia or dysfibrinogenemia.

Fibrinogen Levels  [3.]

Fibrinogen, a key protein in the coagulation cascade, plays a vital role in clot formation and stabilization.  Fibrinogen levels reflect the body's ability to produce fibrin, with low levels indicating impaired clotting ability and high levels suggesting hypercoagulability. 

Measurement of fibrinogen levels complements aPTT and PT testing, providing additional information on the fibrinogen component of clot formation and its implications in various coagulation disorders.

Order aPTT Testing

Click here to compare testing options and order tests for clotting assessment.